XOMA to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Webcast on March 9

XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, March 9, 2016, at 4:30 p.m. Eastern Standard Time to discuss fourth quarter and full year 2015 financial results and provide an update on its endocrine disease portfolio.

The webcast can be accessed via the Investors & Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on May 9, 2016. Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international). 

About XOMA CorporationXOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism. For more information, visit www.xoma.com.

CONTACT: Investor Contacts:
         Ashleigh Barreto, XOMA
         510-204-7482
         [e-mail]  

         Juliane Snowden, The Oratorium Group, LLC
         [e-mail]

         Media Contact:
         Ryan Flinn, W2O Group
         415-946-1059
         [e-mail]